Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Gido Snaterse"'
Publikováno v:
Endocrine Oncology, Vol 3, Iss 1, Pp 1-15 (2023)
11-oxygenated androgens are a class of steroids capable of activating the androgen receptor (AR) at physiologically relevant concentrations. In view of the AR as a key driver of prostate cancer (PC), these steroids are potential drivers of disease an
Externí odkaz:
https://doaj.org/article/c0a626bef6d74e5b8686ba2ae306a4f5
Autor:
Gido Snaterse, Lisanne F. van Dessel, Job van Riet, Angela E. Taylor, Michelle van der Vlugt-Daane, Paul Hamberg, Ronald de Wit, Jenny A. Visser, Wiebke Arlt, Martijn P. Lolkema, Johannes Hofland
Publikováno v:
JCI Insight, Vol 6, Iss 11 (2021)
BACKGROUND Continued androgen receptor (AR) signaling constitutes a key target for treatment in metastatic castration-resistant prostate cancer (CRPC). Studies have identified 11-ketotestosterone (11KT) as a potent AR agonist, but it is unknown if 11
Externí odkaz:
https://doaj.org/article/ad864ce07470475e827abbccf2201326
Autor:
Gido Snaterse, Rosinda Mies, Wytske M. van Weerden, Pim J. French, Johan W. Jonker, Adriaan B. Houtsmuller, Martin E. van Royen, Jenny A. Visser, Johannes Hofland
Publikováno v:
Prostate Cancer and Prostatic Diseases, 26(2), 293-301. Nature Publishing Group
Background: Androgen receptor (AR) ligand-binding domain (LBD) mutations occur in ~20% of all castration-resistant prostate cancer (CRPC) patients. These mutations confer ligand promiscuity, but the affinity for many steroid hormone pathway intermedi
Binding affinity affecting SHBG SNPs do not majorly affect calculated estimates of free testosterone
Autor:
Joeri Walravens, Thiberiu Banica, Den Eynde Tibbert Van, Gido Snaterse, Tim Reyns, Nick Narinx, Leen Antonio, Tom Fiers, Jean-Marc Kaufman, Bruno Lapauw
Publikováno v:
Endocrine Abstracts.
Autor:
Gido, Snaterse, Rosinda, Mies, Wytske M, van Weerden, Pim J, French, Johan W, Jonker, Adriaan B, Houtsmuller, Martin E, van Royen, Jenny A, Visser, Johannes, Hofland
Publikováno v:
Prostate cancer and prostatic diseases.
Androgen receptor (AR) ligand-binding domain (LBD) mutations occur in ~20% of all castration-resistant prostate cancer (CRPC) patients. These mutations confer ligand promiscuity, but the affinity for many steroid hormone pathway intermediates is unkn
Autor:
Jenny A. Visser, Wiebke Arlt, Gido Snaterse, Riet Job van, Hans Hofland, Dessel Lisanne F van, Angela E Taylor, Martijn P. Lolkema
Publikováno v:
Endocrine Abstracts.
Autor:
Job van Riet, Johannes Hofland, Wiebke Arlt, Lisanne F. van Dessel, Jenny A. Visser, Paul Hamberg, Gido Snaterse, Angela E Taylor, Martijn P. Lolkema, Ronald de Wit, Michelle van der Vlugt-Daane
Publikováno v:
JCI Insight.
BACKGROUNDContinued androgen receptor (AR) signaling constitutes a key target for treatment in metastatic castration-resistant prostate cancer (CRPC). Studies have identified 11-ketotestosterone (11KT) as a potent AR agonist, but it is unknown if 11K
Autor:
Gido Snaterse, Lisanne F. van Dessel, Johannes Hofland, Martijn P. Lolkema, Jenny A. Visser, Angela E Taylor, Wiebke Arlt
Publikováno v:
Steroids, 167:108800. Elsevier Inc.
BACKGROUND: Steroid hormones are essential signalling molecules in prostate cancer (PC). However, many studies focusing on liquid biomarkers fail to take the hormonal status of these patients into account. Steroid measurements are sensitive to bias c
Autor:
Johannes Hofland, Jenny A. Visser, Angela E Taylor, Lisanne F. van Dessel, Martijn P. Lolkema, Gido Snaterse, Wiebke Arlt
BackgroundSteroid hormones are essential signalling molecules in prostate cancer (PC). However, many studies focusing on liquid biomarkers fail to take the hormonal status of these patients into account. Steroid measurements are sensitive to bias cau
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64aea9bddabf913df94ebd2d8436e19f
https://doi.org/10.1101/2020.08.05.20164202
https://doi.org/10.1101/2020.08.05.20164202
Publikováno v:
Endocrine-Related Cancer, 24(11), R403-R420. Bioscientifica Ltd
Steroid hormones play a central role in the maintenance and progression of prostate cancer. The androgen receptor is the primary driver of tumor cell proliferation and is activated by the androgens testosterone and 5α-dihydrotestosterone. Inhibition